drugset / Trial / NCT00561951

Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.

NCT00561951

Phase 2 Completed 951 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of fesoterodine in comparison to placebo for overactive bladder.

Timeline

Start
2007-11
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 4 mg Oral
Subject Fesoterodine Other / unclassified 8 mg Oral

Indications